These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36373934)

  • 1. Body mass index (BMI) does not predict responses to psilocybin.
    Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL
    J Psychopharmacol; 2023 Jan; 37(1):107-116. PubMed ID: 36373934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

  • 3. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
    Garcia-Romeu A; Barrett FS; Carbonaro TM; Johnson MW; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):353-361. PubMed ID: 33611977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin and Other Classic Psychedelics in Depression.
    Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D
    Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
    Roseman L; Nutt DJ; Carhart-Harris RL
    Front Pharmacol; 2017; 8():974. PubMed ID: 29387009
    [No Abstract]   [Full Text] [Related]  

  • 9. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
    Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
    Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
    Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.
    Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR
    Front Psychol; 2017; 8():1238. PubMed ID: 28790944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
    Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM
    Eur Neuropsychopharmacol; 2021 Sep; 50():121-132. PubMed ID: 34246868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
    Nygart VA; Pommerencke LM; Haijen E; Kettner H; Kaelen M; Mortensen EL; Nutt DJ; Carhart-Harris RL; Erritzoe D
    J Psychopharmacol; 2022 Aug; 36(8):932-942. PubMed ID: 35924888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin 5-HT
    Erkizia-Santamaría I; Alles-Pascual R; Horrillo I; Meana JJ; Ortega JE
    Biomed Pharmacother; 2022 Oct; 154():113612. PubMed ID: 36049313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.